Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.

ABSTRACT: [This corrects the article DOI: 10.1371/journal.pone.0234103.].

SUBMITTER: PLOS ONE Staff 

PROVIDER: S-EPMC8101907 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature